UBX Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own UBX shares is 41, representing 20.21% of the company's common stock.

JPMORGAN CHASE & CO, in the last quarter, reduced its stake in UBX by -100% restricting it's holding to 0 shares of worth nearly -. CLEARSTEAD ADVISORS, LLC also lessened -100% of the UBX shares from its portfolio, reducing its holding to 0 shares of worth -. CHARLES SCHWAB INVESTMENT MANAGEMENT INC also shunned UBX shares holding by -100% last quarter which brought its holding to 0 shares worth -.

As per its latest 13F filing, MAYO CLINIC increased its stake in UBX by 100% in the last quarter. The institutional holder raised its holding to 157.2 thousand shares having worth more than $430.72K. N/A also added N/A more shares of UBX to its portfolio, raising its holding to - shares of worth -. N/A also increased its UBX shares holding by N/A which brought its holding to - shares worth -.

The insider with the most stakes in UBX is David Nathaniel E , President at the company. Additionally, UBX stock is highly held by Chief Executive Officer Ghosh Anirvan and Chief Medical Officer Dananberg Jamie among others.

Company executives, directors, and other insiders own 1.31% percent of Unity Biotechnology, Inc.'s stock. Within the last six months, there have been 3 transaction(s) in which UBX insiders have sold stock, totaling 717 shares. Insiders that have sold shares include NGUYEN ALEXANDER HIEU, GHOSH ANIRVAN, and SULLIVAN LYNNE MARIE.

There have been 0 transaction(s) during the past 6-months in which Unity Biotechnology, Inc. insiders have bought stock, totalling 0 shares

Around 156.54K Unity Biotechnology, Inc. shares are held by insiders, which represents about 1.31% of UBX stock.

UBX President, David Nathaniel E holds the largest portfolio of the company's shares. UBX shares owned by David total nearly 624.7 thousand.

JPMORGAN CHASE & CO is the largest institutional owner in UBX which holds 0 shares worth - or 0% of the total UBX shares outstanding followed by CLEARSTEAD ADVISORS, LLC with ownership of 0 shares representing 0% of the UBX ownership. CHARLES SCHWAB INVESTMENT MANAGEMENT INC is the third largest stakeholder with 0 shares or 0% of the ownership worth more than -.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the UBX is concerned, it is a stock which is optionable.

Number of UBX shares short is 222.26K. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 16.85M shares of UBX are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, UBX has 14.66M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for UBX is 0.73.